ATS GUIDELINES Bundle

Outpatient Community-Acquired Pneumonia

American Thoracic Society Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/91869

Contents of this Issue

Navigation

Page 6 of 7

Table 3. Recommended Antimicrobials for Outpatient Treatment of CAP (continued) Antimicrobial Cephalosporins Ceftriaxone (Rocephin® ) Cefpodoxime proxetil (Vantin® ) Cefprozil (Cefzil ® ) Cefuroxime axetil (Ceftin® ) Cefditoren pivoxil (Spectracef ® ) Cefdinir (Omnicef® ) ) Fluoroquinolones Moxifloxacin (Avelox® Gemifloxacin (Factive® ) Levofloxacin (Levaquin® ) Macrolides Azithromycin (Zithromax® ) Clarithromycin (Biaxin® (Biaxin XL® ) Penicillins Amoxicillin (Amoxil ® , others) PO 1 g tid † > Dose listed is specified for empirical therapy based on presence of risk factors for resistance, lower doses are adequate for penicillin- susceptible S. pneumoniae; lacks activity against atypical pathogens and β-lactamase producers 5 ) Erythromycin (Ery-tab® , others) PO 500 mg qd 1st 250 mg qd × 4 OR 2 g extended release x 1 dose PO PO PO 500 mg q12h 2 x 500 mg q24h 500 mg q6-8h day, then > Macrolides active against most common pathogens including atypical pathogens > Erythromycin poorly tolerated and less effective against H. influenzae IV, PO PO IV, PO 400 mg qd 320 mg qd 750 mg qd †‡ > Active against S. pneumoniae (including penicillin- resistant strains), H. influenzae, methicillin- susceptible S. aureus, and atypical pathogens Route IV, IM PO PO PO PO PO Adult Dose* 1 g q24h 200 mg q12h 500 mg q12h 500 mg q12h † 400 mg bid 300 mg q12h Comments > Ceftriaxone is an alternative to high-dose amoxicillin when parenteral therapy is feasible > Oral cephalosporins active against most S. pneumoniae and nearly all H. influenzae > All cephalosporins inactive against atypical pathogens

Articles in this issue

view archives of ATS GUIDELINES Bundle - Outpatient Community-Acquired Pneumonia